TNFRSF8 and neoplasm: reported that co-targeting of CD30 in CEA- and TAG72-targeted CAR T cells enhanced T cell activity against CD30-negative tumor cells via elimination of CD30+ T cells, which suppress the cytotoxic T cell response.